Anika Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (ticker: ANIK) is a U.S.-based company listed on the NASDAQ market in the United States. For French-, Belgian- and Swiss-based investors, Anika is best viewed as a specialty healthcare and orthopedic company focused on early-intervention orthopedics, osteoarthritis pain management, and regenerative solutions. Founded in 1992 and headquartered in Bedford, Massachusetts, the company has built its platform around hyaluronic acid (HA), a naturally occurring polymer that plays a role in joint health and tissue function. ([sec.gov](https://www.sec.gov/Archives/edgar/data/898437/000114036126017488/ny20067128x1_def14a.htm?utm_source=openai)) Anika’s business is organized around developing, manufacturing, and commercializing differentiated orthopedic products. Its main osteoarthritis pain management franchise includes Monovisc, Orthovisc, and Cingal, all centered on HA-based treatment approaches intended to help relieve knee pain and improve function. Its regenerative solutions portfolio includes Integrity, Hyalofast, and Tactoset, which target tendon repair, cartilage regeneration, and bone repair support. The company also operates through a partnership model in key markets; notably, Monovisc and Orthovisc are marketed and sold exclusively through J&J MedTech in the United States, while other products are distributed through international commercial partners. ([anika.com](https://anika.com/about-anika/?utm_source=openai)) From a competitive standpoint, Anika is a focused niche player rather than a broad-based medtech conglomerate. Its differentiation comes from long-standing expertise in HA-based biomaterials, a concentrated orthopedic portfolio, and a strategy aimed at high-value clinical areas. This specialization can be attractive for investors seeking exposure to orthopedics and regenerative medicine, but it also means the company is more sensitive to regulatory timing, reimbursement dynamics, and commercial execution than larger diversified peers. Recent reporting indicates a mixed backdrop: international commercial activity and the Integrity Implant System have shown momentum, while U.S. OA pain management has faced pricing pressure on Monovisc and Orthovisc. ([sec.gov](https://www.sec.gov/Archives/edgar/data/898437/000114036126017488/ny20067128x1_def14a.htm?utm_source=openai)) Recent milestones have been important. Effective February 1, 2026, Cheryl Blanchard transitioned to Executive Chair and Steve Griffin became President and CEO. In 2025, the company continued advancing its pipeline, including the FDA PMA submission for Hyalofast and continued regulatory work related to Cingal. Management has also highlighted growth in the Commercial Channel and progress in regenerative solutions, reinforcing the view that Anika is working to rebalance its portfolio toward higher-growth, higher-margin orthopedic opportunities. For investors, ANIK is a specialized healthcare name with meaningful pipeline optionality, listed on NASDAQ in the United States, and best evaluated through the lens of product execution, regulatory catalysts, and partner-led commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/898437/000114036126017488/ny20067128x1_def14a.htm?utm_source=openai))